Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial

Soudani Marghli1,2*, Chafiaa Bouhamed1,2, Amira Sghaier1,2, Nabil Chebbi2, Insaf Dlala1,2, Samia Bettout1,2, Achref Belkacem2, Sarra Kbaier3, Nahla Jerbi1,2 and Abdelouahab Bellou4,5

Abstract
Background: The additive benefit of inhaled corticosteroid when used with systemic corticosteroid in acute asthma is still unclear. The objective of this study was to assess the effect of high and repeated doses of inhaled budesonide when combined with the standard treatment of adult acute asthma.

Methods: It was a prospective double-blind randomized controlled study performed in the emergency department (ED) from May 1, 2010 to February 28, 2011 (ClinicalTrials.gov, NCT04016220). Fifty patients were included and were randomized to receive intravenous hydrocortisone hemisuccinate in association with nebulized budesonide (n = 23, budesonide group) or normal saline (n = 27, control group). Nebulization of budesonide or saline was done in combination with 5 mg of terbutaline every 20 min the first hour, then at 2 h (H2), and 3 h (H3). All patients received standard treatment. Efficacy and safety of inhaled budesonide were evaluated every 30 min for 180 min.

Results: A significant increase in peak expiratory flow (PEF) was observed in both treatment groups at evaluation times. The increase in PEF persisted significantly compared to the previous measurement in both groups. There was no significant difference in the PEF between the two groups at evaluation times. There was also no statistically significant difference between the two groups in the evolution in the respiratory rate and heart rate. There was also no statistically significant difference between the two groups in the rate of hospitalization, the discharge criteria before the end of the protocol.

Conclusions: Considering its limited power, our study suggests that the association of nebulized budesonide with hydrocortisone hemisuccinate has no additional effect over the use of hydrocortisone alone in adults’ acute asthma managed in the ED.

Keywords: Acute asthma, Nebulized budesonide, Systemic steroid, Emergency department
Background
Inhaled short-acting bronchodilators (short-acting β2-agonists alone or in combination with anti-cholinergic drugs), systemic corticosteroids (SCS), and adequate oxygenation are the basis of the treatment of moderate -to-severe asthma in the emergency department (ED) [1, 2]. Although, SCS represent the standard of care for severe asthma exacerbation in the ED, it is well known that SCS require 6 to 24 hours to produce effects on pulmonary function or reduction of hospitalization [3–5]. Recently a renewed focus on the use of inhaled corticosteroid (ICS) function or reduction of hospitalization [3–5]. Several studies have shown an effect 90 to 120 minutes of ICS on pulmonary function in the treatment of adult [6, 7] and pediatric [8–12] acute asthma. This effect suggests a local non-genomic mechanism, related to a vasoconstriction of smooth muscle on mucosal vessels causing a blood flow reduction in the airway mucosa [13–15]. A published systematic review on the effectiveness of ICS in the ED treatment of acute asthma [16] concluded that there is a beneficial effect compared to placebo. But studies, all in children, comparing ICS to SCS showed contradictory results [11, 17–20]. In the ED setting; there is insufficient evidence that ICS therapy alone can be used with confidence instead of SCS. The additive benefit of ICS when used with SCS is still under investigation and there is insufficient evidence that ICS significantly change pulmonary function or clinical scores in addition to SCS in acute asthma [16]. The objective of our clinical trial was to compare the additive effect of high and repeated doses of inhaled budesonide combined to the standard treatment in adult acute asthma. Our primary hypothesis was that the association of ICS to SCS would be more effective than SCS alone in improving pulmonary function.

Methods

Patients
We recruited adult patients with acute asthma who were managed in the ED of Tahar Sfar Hospital in Mahdia, Tunisia from May 1, 2010 to February 28, 2011. The inclusion criteria were: diagnosis criteria of asthma of the Global Strategy for Asthma Management and Prevention [21]; age between 18 and 50 years; a peak expiratory flow (PEF) rate less than 50% of predicted value; one or more of the following features were present: accessory muscle activity, a heart rate greater than 110 beats/minute, a respiratory rate greater than 25 breaths/minute, a limited ability to speak; and an expressed willingness to participate in the study, with written informed consent obtained. Patients were excluded if they had a temperature higher than 38°C, or a history of cardiac, hepatic, renal, or other medical disease, or if they were pregnant.

The study was recorded in ClinicalTrial.gov registry under the number: NCT04016220 on 11/07/2019. The local institutional ethics committee (Comité d’Ethique de l’hôpital Tahar Sfar, Mahdia, Tunisia) approved the study. Written, informed consent was obtained from all participants.

Design
This study was a prospective, randomized, double-blind, controlled trial.

Inclusion of patients in the study was ensured during the day and on working days only. Included patients received the assigned treatment after randomization and contained in sealed envelopes and that neither the treating physician nor the patient knows the nature of the product. Randomization was performed using the GraphPadStateMate® software. Only the principal investigator prepared the drug or placebo in syringes after the envelopes were opened. Budesonide and placebo were identical in appearance and neither the clinician nor the patient can distinguish them. The principal investigator was not involved in the enrolment of participants, assignment to interventions, therapeutic care, and statistical analysis. Patients in the experimental group received a first nebulization of 5 mg of terbutaline (Bricanyl®, AstraZeneca: 5mg/2ml solution) in combination with 0.5 mg of ipratropium bromide (Ipratropium®, AstraZeneca: 0.5 mg/2ml solution) and 0.5 mg of budesonide (Pulmicort®, AstraZeneca, 0.5 mg/2ml solution) followed by frequent nebulization of a combination of terbutaline (5mg) and budesonide (0.5mg) at 20, 40, 60 and 120 min. Patients in the control group received a first nebulization of 5 mg of terbutaline (Bricanyl®, AstraZeneca: 5mg/2ml solution) in combination with 0.5 mg of ipratropium bromide (Ipratropium®, AGUETTANT: 0.5 mg/2 ml solution) and 0.5 mg of budesonide (Pulmicort®, AstraZeneca, 0.5 mg/2 ml solution) followed by frequent nebulization of a combination of terbutaline (5mg) and budesonide (0.5mg) at 20, 40, 60 and 120 min. Patients in the control group received a first nebulization of 5 mg of terbutaline (Bricanyl®, AstraZeneca: 5mg/2ml solution) in combination with 0.5 mg of ipratropium bromide (Ipratropium®, AGUETTANT: 0.5 mg/2ml solution) and placebo (normal saline: 2 ml) followed by frequent nebulization of a combination of terbutaline (5mg) and placebo at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg IV) and oxygen at a flow rate of 7 L/min as a carrier gas for nebulization (Fig. 1).

Measures
The parameters collected concerned the demographic characteristics, the severity of asthma (background treatment, previous hospitalization and history of mechanical ventilation), the duration of symptoms before presentation, which specifically included how long the patient had been wheezing and shorter of breath than usual, a decline in the PEF, if available, was considered, and the clinical criteria of severity.

The following variables were measured and calculated for each patient immediately before treatment and then
every 30 minutes for 3 hours after treatment initiation: 
PpEF, respiratory rate, involvement of the accessory respira-

tory muscles, dyspnea, heart rate, blood pressure. 
The PEF was measured by a peak-flow meter (Micro-

PeaK® Cardinal Health, UK); the highest of 3 successive 
measurements was used. Dyspnea was assessed by the 
patient’s own sense of difficulty breathing and a value 
was assigned on a scale of 0 to 3; 0: absent, 1: minimal, 
2: moderate, 3: severe. The clinical aggravation requiring 
the use of mechanical ventilation led the interruption of 
the protocol. At the end of the protocol the following side 
effects were sought by the patient’s interrogation: palpita-
tions, tremor, anxiety, headache, and dry mouth. The 
decision to release or to admit the patient was made at 
the end of the protocol (180 minutes) by the senior physi-

cian without knowledge of the patient’s treatment group 
assignment. It requires the meeting of all the following 
criteria: no involvement of the sternocleidomastoid mus-
cles, the sibilant rails were considered minimal or absent, 
free of dyspnea, the PEF > 60% of the predicted [8]. At the 
end of the emergency department, patients were treated 
with prednisone 40mg/ day for 7 days, short-acting beta-
mimetics and an appointment at the pneumology outpa-
tient consultation after 1 week.

Primary outcome measures were defined as follow: 
improvement in PEF and reduction in admission rate. 
Secondary outcomes were clinical measures, respiratory 
and heart rates, side effects, and proportion of patients 
that reached the discharge threshold during the 3 hours 
of treatment for each group.

Statistical analysis
Continuous variables were expressed as mean ± standard 
development (SD) or as median (25–75% interquartile range, 
IQR) as appropriate while verifying the normality with 
a Kolmogorov-Smirnov test. Categorical variables were 
summarized using numbers and percentages. Baseline 
data of the two treatments were compared using Student’s 
t test for normally distributed independent samples, or the 
Mann-Whitney U test for no normally distributed contin-
uous variables. Fisher’s exact test was used for categorical 
variables. A p value of less than0.05 using a two-tailed test 
was taken as significant for all statistical tests. Changes 
in PEF, HR, RR, and dyspnea scale were evaluated using 
repeated measures analysis of variance (ANOVA), with 
one between-subject factor (budesonide-placebo groups) 
and one within-subject factor (time). One-way repeated 
measures ANOVA was used to compare baseline values 
for each variable. At the beginning of the study we deter-
mined the sample size needed to detect a 20 L/min dif-
fERENCE IN PEF variation between groups, the calculations 
were based in a previous study which showed a variation 
between baseline and 40 min evaluation was 65 ± 38 l/

min [22]. Statistical power calculation showed that 58
subjects per group was needed with $\alpha = 0.05$ and $\beta = 0.20$ (ie, with 80% power). Due to the poor recruitment of patients, the study was stopped.

**Results**

**Description of study cohort**

During the study period 62 patients were initially included. Eight patients were excluded, five patients were over 50 years old, one patient had a fever and two patients were pregnant. The remaining 54 patients were randomized into 25 patients in the budesonide group and 29 in the control group. During the protocol two patients from each group, did not complete the protocol and left the ED prematurely (Fig. 2). The analysis consisted of 23 patients in the budesonide group and 27 patients in the control group. Acute asthma was inaugural in 10% of patients ($n = 5$) and 54% of patients ($n = 27$) had an asthma lasting less than or equal to 5 years. The demographic characteristics and the severity of asthma were comparable in both groups (Table 1). Both groups were comparable at inclusion (Table 2).

**Evaluation of treatment effects**

**PEF**

The PEF increased significantly at the different evaluation times compared to the previous evaluation times until 150 min for the budesonide, whereas this statistical significance continues until 180 min in the control group (Fig. 3). The average PEF at 180 min was $308 \pm 107$ l/min and $321 \pm 99$ l/min respectively in the budesonide ($n = 22$) and control ($n = 27$) groups. The increase in PEF at 180 min was 139 and 121% respectively for the budesonide group and control with a difference of 18% (95% CI [−62 to 98%]). We did not find statistically significant

| Table 1 Characteristics of included patients in the trial |
|----------------------------------------------------------|
|                                                          |
| **Budesonide**                                           | **Control**   | **p** |
| $N = 23$                                                 | $N = 27$      |       |
| Age, y, mean (SD)                                        | 38 ± 10       | 33 ± 11 | 0.086 |
| Sex M                                                    | 9(39)         | 11(41) | 0.908 |
| Long-term treatment                                      |               |       |
| Long acting beta2-mimetics                               | 9(39)         | 7(26)  | 0.318 |
| Inhaled corticosteroids                                  | 11(48)        | 14(52) | 0.777 |
| Systemic corticosteroids                                 | 1(4)          | 0      |       |
| Theophylline                                             | 4(17)         | 1(4)   | 0.167 |
| History of hospitalization for acute asthma              |               |       |
| 1 hospitalization                                        | 5(22)         | 8(30)  | 0.526 |
| 2 hospitalizations                                       | 2             | 4      |       |
| 3 hospitalizations                                       | 1             | 4      |       |
| History of mechanical ventilation for acute asthma       |               |       |
|                                                         | 2(9)          | 2(9)   | 0.898 |

All data except age are presented as number (percentage)
difference in the PEF between the two groups at the different evaluation times.

RR

We found that the decrease in RR was statistically significant compared to baseline only from 60 min for both groups (see Additional Figure 1). There was no statistically significant difference in RR at the different evaluation times between the two groups.

Dyspnea scale

The decrease in dyspnea scale was no longer significant compared to the previous evaluation time from 90 min in both groups. There was no statistically significant difference in the dyspnea scale between the two groups (see Additional Figure 2).

HR

There was a tendency for an increase in HR compared to the baseline in the control group, which became statistically significant at 120 and 180 min, while the variation was not statistically significant in the budesonide group (see Additional Figure 3). HR tends to be higher in the control group compared to the budesonide group only at 180 min (102 ± 17 beats/min in the control group vs 94 ± 17 beats/min in the budesonide group, p = 0.096).

Outcome and side effects

The hospitalization rate was 35 and 33% in the budesonide and control groups, respectively, without significant difference (Table 3). In intent-to-treat analysis, there was no statistically significant difference between the two groups, 40% in budesonide group vs 38% in control group (p = 0.876). Similarly, the proportion of patients with

Table 2 Baseline characteristics at inclusion in the Emergency Department

|                      | Budesonide N = 23 | Control N = 27 | p     |
|----------------------|-------------------|----------------|-------|
| β2 used within past 48 h | 14 (61)           | 13 (48)        | 0.368 |
| Corticosteroids used within past 7 days | 1/21 (5)          | 5/25 (19)      | 0.054 |
| Duration of the crisis, h | 35 ± 46           | 49 ± 80        | 0.474 |
| Respiratory rate, breaths /min | 30 ± 6           | 29 ± 9         | 0.636 |
| SatO2, %              | 94 ± 5            | 95 ± 4         | 0.548 |
| PEF, L/min            | 153 ± 69          | 163 ± 61       | 0.588 |
| PEF, % of the predicted | 31 ± 14           | 33 ± 12        | 0.453 |
| PEF ≤ 30% of the predicted | 6/19 (32)        | 8/26 (31)      | 0.954 |
| Systolic arterial blood pressure, mmHg | 121 ± 15          | 120 ± 17       | 0.578 |
| Diastolic arterial blood pressure, mmHg | 70 ± 11           | 73 ± 11        | 0.531 |
| Heart rate, beats/min | 99 ± 19           | 92 ± 26        | 0.339 |

All data are presented as number (percentage) or mean (±SD)

β2 short-acting β2-mimetics, h hour, PEF Peak expiratory flow

Fig. 3 Evolution of PEF. *Values in both groups were significantly better than previous evaluation. **p < 0.05 vs T150 in control group. PEF: peak expiratory flow
discharge criteria before the end of the protocol (180 min) and the incidence of side effects were comparable between the two groups.

**Evaluation in the most severe patients**

Fifteen patients had a PEF at baseline of less than 30% of the predicted value. The clinical characteristics of severity of the asthma were comparable between the two groups (see Additional Table 1). PEF increased significantly at the different evaluation times compared to the baseline and there was no statistically significant difference in the PEF between the two groups at the different time periods. However, this gain in PEF is no longer significant compared to the previous evaluation times from 60 min and 90 min for budesonide and control groups, respectively. The increase in PEF at 180 min was 182% ± 83% in the budesonide group and 149% ± 93% in the control group (p = 0.529). There was no statistically significant difference between the two groups in the decrease of RR, dyspnea scale, and HR. Hospitalization rate was 67 and 33% in the budesonide group and control group respectively, without reaching a statistically significant difference. There was no statistically significant difference between the two groups in discharge criteria and incidence of side effects (see Additional Table 2).

**Discussion**

The objective of this randomized controlled double-blind trial was to compare the efficacy and tolerability of the combination of repeated nebulization of budesonide with HCHS i.v. versus HCHS i.v. alone in severe acute asthma in adults managed in the ED. The results of the trial did not find a statistically significant difference between the two groups in the rate of hospitalization, the discharge criteria before the end of the protocol, the improvement of PEF, and the decrease in RR. There was also no statistically significant difference between the two groups with regard to decreased dyspnea. HR was higher in the control group at the end of the protocol. Finally, there was no difference in the rates of side effects between the two treatment groups.

We have excluded patients over the age of 50 because the increased incidence of morbidities and in the context of the emergency, it is sometimes difficult to eliminate other pathologies such as chronic obstructive pulmonary disease. Probably for this reason that Rodrigo G [4, 7, 8] also included patients between the ages 18 to 50 in his work evaluating inhaled corticosteroids therapy in the emergency department on patients with acute asthma. On the other hand, only 48–52% of the study participants used inhaled corticosteroids in the baseline before emergency department admission because this drug is relatively expensive. In a study comparing the effectiveness of nebulized salbutamol and adrenaline in acute severe asthma in ICU, inhaled corticosteroids were used at 0 and 18% [22]. Furthermore, it is not likely that the results are influenced by the severity of the patients in the budesonide group since 4% of the patients were under systemic corticosteroids because there is no significant difference between groups at inclusion and even in the sub-group analysis for the more severely affected participants there was no significant difference in outcomes between groups.

SCS associated with repeated nebulization of mimetic beta2, anticholinergics and adequate oxygenation are the basis of the treatment for severe acute asthma in the ED [3, 4]. In addition to the delayed anti-inflammatory effect of corticosteroids which happens within a few hours or days, the acute therapeutic response of ICS indicates a different mechanism of action of topical character (nongenomic action) [13]. Evidence suggests that ICS decreases airway blood flow by modulating sympathetic nervous system control through potentiating vasoconstriction by increased noradrenergic neurotransmission in the airway vessels [15, 23]. This effect is transient, it reaches its peak effectiveness in 30 minutes then returns to basal value between 60 to 90 min [24]. In addition, the decrease in airway blood flow is likely to increase the action of inhaled bronchodilators by diminishing their clearance from the airway [25]. Thus, simultaneous administration of ICS and bronchodilators may have a rapid clinical effect. New data on the non-genomic mechanism of action of ICS have opened in recent years a new pathway on the treatment of acute asthma. The first placebo-controlled trials in adults [6, 7] and in children [9–11] were favorable for the use of ICS in acute asthma, showing an improvement in physiological parameters. The combination of 12 studies in a meta-analysis published in 2012 including 960 patients indicates a significant reduction in hospital admissions in patients with ICS than placebo [16]. Approximately eight patients would require ICS treatment to prevent one admission.

| Table 3 Outcomes and side effects |
|-----------------------------------|
|                                | Budesonide | Control | Absolute risk reduction (95% CI) |
| Hospitalization, n(%)            | 8(35)      | 9(33)   | −2(−28 to 24)                  |
| Discharge criteria before 180 min, n (%) | 10(44)    | 12(44)  | −0.9(−28.6 to 26.7)            |
| Side effects, n (%)              | 8(35)      | 9(33)   | −2(−28 to 24)                  |
| Palpitation, n                   | 6          | 6       |
| Tremor, n                       | 5          | 3       |
| Headache, n                     | 2          | 2       |
| Dry mouth, n                    | 2          | 4       |

All data are presented as number (percentage)
The benefit effect in reducing hospital admissions persist in the subgroup ICS plus SCS than SCS alone, however there was heterogeneity between studies [16]. Other studies comparing ICS to SCS showed contradictory results [11, 17–20, 26–28]. In six studies including children with moderate acute asthma, ICS were comparable to SCS regarding improvement in physiological parameters with a tendency to have an earlier beneficial effect [11, 17–19, 26, 27]. In more severe children, Schuh et al. [29] found a greater improvement in the maximum expiratory volume per second (18.9% vs 9.4%) and a reduction in the hospitalization rate (10% vs 31%) in the group receiving prednisone (2 mg / kg tablet) than in the inhaled fluticasone group (single dose of 2 mg). In contrast, in the single adult acute asthma trial comparing the effects of repeated fluticasone inhalation versus hydrocortisone i.v., Rodrigo found early improvement in physiological parameters in the fluticasone group [30]. The benefit was more evident in the more severe patients (FEV$_1 < 1$L) with a decrease in hospitalizations (38% in the fluticasone group vs 25% in the hydrocortisone group, $p = 0.05$). The inclusion of these studies in the meta-analysis cited above did not find a clear advantage for either ICS or SCS in terms of hospital admissions [16] but there was significant heterogeneity between studies. The authors of this meta-analysis suggested further investigations in order to rule out the sources of heterogeneity due to the limited number of studies included and the limitation of the judgment criteria. Nevertheless, these comparative studies have had the additional advantage of explaining the mechanism of action of corticosteroids. In two studies, it was found a reduction in the number of eosinophils in the blood after use of prednisone and a reduction in the number of eosinophils in the airways after use of fluticasone suggesting a local anti-inflammatory effect of ICS [31].

Taken together, these results reinforced the choice of using ICS in association with SCS in our study. Probably the ICS cannot control all the inflammatory mechanisms encountered in asthma. The determination of the additional benefits of the association of ICS with the usual treatment in acute asthma in adults has not been extensively studied. Only few randomized controlled trials have been published to date [32–35]. In one study that included adults with a methodology similar to our RCTs, Guttman et al. included 60 acute asthma patients in the ED [32]. All patients received a nebulization of salbutamol (base, 30 min, 1h, 2h, 4h, 6h, 8h and 10h) and 80mg of methylprednisolone at i.v. at the inclusion and 40mg after 6 hours. After randomization, patients in the experimental group received 7mg over 8 hours (base, 30 min, 1 h, 2h, 4h, 6h and 8h) of beclomethasone dipropionate (BDP) through a metered dose inhaler. A placebo was administered in the same way in the control group. After initial treatment, a significant increase in FEV1, predicted FEV and PEF percentage change ($p < 0.001$) was associated with a decrease in dyspnea score and RR ($p < 0.03$) in the two groups. At 120 minutes, a plateau was reached and only minor changes were observed thereafter. Variations in spirometry, dyspnea score, and vital parameters did not differ between the two groups at the different evaluation times. Authors concluded that the addition of BDP to standard therapy (methylprednisolone IV and β agonist) has no additional benefits over standard treatment. In this study, the PEF evolution in each group was similar whereas in our study the gain of the PEF was no longer significant from 150 min compared to the previous evaluation time for the budesonide group while it persisted significant until the end of the protocol in the control group. We suspect that our patients were more severe than those in Guttman et al. probably, the lower the PEF is the better the response to the combination of ICS plus SCS. We did not confirm our hypothesis in subgroup of patients ($n = 15$) with a PEF < 30% of the predicted value of our trial. A trial involving a larger number of more severe patients could answer this question. The second explanation is the time interval of administration of ICS which was 20 min for the first four administrations in our protocol and which was more prolonged in Guttman et al. study with 30 min for the first two administrations and 60 min later. In fact, it has been demonstrated that the non-genomic effect of ICS is transient with a maximum of 30–60 min after administration [24] and it could be of interest to administer repeatedly at time intervals of less than 30 min [25]. Finally, fluticasone and budesonide have been shown to produce more effect than BDP [36]. In another study Bateman et al. [33] compared the efficacy and safety of budesonide / formoterol with formoterol alone in 115 adult asthma patients who showed evidence of refractoriness to a short-acting β$_2$ agonist. They have shown a similarly rapid relief of acute bronchoconstriction in the two treatment groups and there were no statistically significant difference between groups for treatment success and treatment failure. In a pediatric randomized, double-blind, controlled trial involving children aged 6 months to 18 years with acute asthma in the ED; Sung et al. investigated the clinical effects of nebulized budesonide [34]. All patients received oral prednisone at a dose of 1mg / kg and nebulized salbutamol at a dose of 0.15 mg / kg every 30 minutes for the first three nebulization and each hour for 4 h. The experimental group ($n = 24$) received a single dose of 2,000 μg (4 ml) of nebulized budesonide and the control group ($n = 20$) received a nebulization of four ml of physiological saline. The primary objective of the study was a two-point change in the Pulmonary Index Score (PIS) that was correlated with the predicted FEV1 and hospitalization rate.
in a previous study [37]. This study did not show a statistically significant difference between the two groups. However, a median time of 1 h was found in the budesonide group compared to 2 h in the control group (p = 0.06) to achieve clinical improvement (two point decrease in the PIS) and the number of hospitalized patients was higher in the control group than in the budesonide group (5 vs 2, p = 0.22). Analysis of the survival curve showed that the ED discharge time was shorter in the budesonide group (p = 0.02). In a recent study, Upham et al. did not find statistically significant difference in a randomized trial of 169 acute asthma patients aged two to 18 years distributed into two groups who received in addition to the administration of albuterol, ipratropium bromide and prednisone (2mg / Kg with a maximum of 60mg) either a single dose of 2 mg (8 ml) of nebulized budesonide or the same amount of nebulizing physiological saline [35].

Limitations
Our study has some limitations. First, the study lacks power to demonstrate a difference in the effect of treatment between the two treatment groups if it exists. Second, randomization resulted into two groups comparable to baseline and to control secondary attrition bias at premature discontinuation of treatment we replaced the missing data with an adverse event and conducted an intention-to-treat. The two groups were treated in the same way and differed only in the type of treatment administrated. The hospitalization decision was also based on objective criteria defined in advance. Moreover, the absence of difference between the two treated groups does not differ from the results of the single study carried out in adults. However, many statistical tests have been done in this study inflating type I error. The clinical relevance of our results does not differ from other studies based on respiratory function assessment. PEF was used as the standard criterion for evaluating the efficacy of bronchodilators in acute asthma, but when it was used to evaluate the benefits of corticosteroid therapy it was not effective [38, 39]. In a meta-analysis that evaluated the effects of corticosteroids in acute asthma, Rowe et al. did not find a difference in the PEF between the corticosteroid group and the placebo group while they observed a decrease in hospitalizations, duration of visit to ED and relapses in the corticosteroid group [40].

Conclusion
Considering its limited power, our study suggests that the association of nebulized budesonide with hydrocortisone hemisuccinate has no additional effect over the use of hydrocortisone alone in adults’ acute asthma managed in the ED.

Abbreviations
BDP: Beclomethasone dipropionate; ED: Emergency department; FEV1: Forced expiratory volume in 1 second; HCHS: Hydrocortisone hemisuccinate; HR: Heart rate; ICS: Inhaled corticosteroid; IQR: Interquartile range; PEF: Peak expiratory flow; PIS: Pulmonary Index Score; RR: Respiratory rate; SCS: Systemic corticosteroids; SD: Standard deviation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12873-022-00691-9.

Acknowledgements
The authors would like to thank professor Fekri Abroug for his advice.

Authors’ contributions
SM created the research idea, supervised all aspects of the study and takes responsibility for the paper as a whole; CB, and AS conceived this study; SB, ID, NC and Achref B acquired the data; NJ, SK, and CB managed and analyzed the data; SM and Abdelouahab B interpreted results; drafted the manuscript and all authors contributed substantially to its revision. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.

Funding
No funding.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The local institutional ethics committee (Comité d’éthique de l’hôpital Tahar Sfar, Mahdia, Tunisia) approved the study. The authors declare and confirm that all methods performed in the present study were carried out in accordance with Declaration of Helsinki. Written, informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Faculty of Medicine of Monastir, University of Monastir, 5019 Monastir, Tunisia. 2 Emergency Department, Research Unit «Douleur thoracique», URI 75P09, Tahar Sfar University Hospital, 5100 Mahdia, Tunisia. 3 Faculty of Medicine of Sousse, University of Sousse, 4002 Sousse, Tunisia. 4 Institute of Sciences in Emergency Medicine, Department of Emergency Medicine, Guangdong provincial people’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, People’s Republic of China. 5 Department of Sousse, University of Sousse, 4002 Sousse, Tunisia.
References

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk BJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:543–73.

2. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc. 2004;1:1235–8.

3. Rodrigo G, Rodrigo C. Corticosteroids in the emergency department treatment of acute asthma: an evidence-based evaluation. Chest. 1999;116:285–95.

4. D’Urso S, Buda EP, Martelli G, Smeriglio A. Inhaled corticosteroids: a comparison with oral corticosteroids in severe asthma. J Bronchol. 2001;8:14–8.

5. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139:355–70.

6. Afifolito M, Gittman A, Colacino A, Danka J, Tsellis C, Stern E, et al. Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: A randomized clinical trial. Ann Emerg Med. 1999;33:304–9.

7. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998;157:698–703.

8. Rodrigo GJ, Rodrigo C.Triple inhaled drug protocol for the treatment of acute severe asthma. Chest. 2003;123:1908–15.

9. Singh GC, Banejee S, Sumanidaswamy HM. Inhaled budesonide in acute asthma. J Pediatr Child Health. 1999;35:483–7.

10. Tsai YG, Lee MY, Yang KD, Chu DM, Yuh YS, Hung CH. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr. 2001;139:433–7.

11. Milani GK, Rosario Filho NA, Riedi CA, Figueiredo BC. Nebulized budesonide to treat acute asthma in children. J Pediatr. 2004;80:106–12.

12. Chen AH, Zeng GQ, Chen RC, Zhan JY, Sun LH, Huang SA. Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. Respir Med. 2013;18:47–52.

13. McFadden ER. Inhaled glucocorticoids and acute asthma: therapeutic breakthrough or non-specific effect. Am J Respir Crit Care Med. 1998;157:677–8.

14. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4:446–56.

15. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc. 2004;1:1235–8.

16. Edmonds ML, Milan SJ, Camargo CA Jr, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD002178.

17. Scarfone RJ, Losellete JW, Wiley JF.2nd, Decker JM, Henretig FM, Joffe MD. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med. 1995;26:480–6.

18. Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovich M. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol. 1998;102:605–9.

19. Devidayal N, Singh S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999;88:835–40.

20. Arulparithi CS, Babu TA, Ravichandran C, Santhanam I, Sathyamurthi B, Parivathini S, et al. Efficacy of nebulized budesonide versus oral prednisolone in acute severe asthma. Indian J Pediatr. 2015;82:328–32.

21. Global Initiative of Asthma. Global Strategy for Asthma Management and Prevention, 2018. Available from: www.ginasthma.org.